The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

In microsatellite instability (MSI)/mismatch repair-deficient (dMMR) gastrointestinal cancers, the optimum therapy after the progression of immune checkpoint inhibitors (ICIs) is yet unknown. Here, we compared the efficacy of programmed death 1 (PD1)/programmed death ligand-1 (PD-L1) inhibitors plus other therapy and chemotherapy with or without targeted therapy in MSI/dMMR gastrointestinal cancer patients after progression on anti-PD1/PD-L1 monotherapy.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Cancers (Basel)

Title: Cancers

Publisher: MDPI AG

ISSN: 2072-6694

ISSN (Print): 2072-6694

Publication date (Electronic): Oct 21 2022

Volume: 14

Issue: 20

Affiliations

[1 ] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, 52 Fucheng Road, Haidian District, Beijing 100142, China.

[2 ] Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.

[3 ] Department of Medical Oncology, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310058, China.

[4 ] Department of Medical Oncology, Peking University First Hospital, Beijing 100034, China.

[5 ] Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen 361005, China.

[6 ] Department of Oncology, Henan Provincial People's Hospital/People's Hospital of Zhengzhou University/People's Hospital of Henan University, Zhengzhou 450001, China.

[7 ] Department of Medical Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai 264099, China.

[8 ] Department of Oncology, Dalian University Affiliated Xinhua Hospital, Dalian 116021, China.

[9 ] Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

[10 ] Department of Digestive Internal Medicine, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011, China.

[11 ] Medical Affairs, 3D Medicines, Inc., Shanghai 201321, China.

Article

Publisher Item ID: cancers14205158

DOI: 10.3390/cancers14205158

PMC ID: 9601260

PubMed ID: 36291942

SO-VID: e8e41c5b-a458-4766-8b91-402506f23d3b

History

Keywords: resistance,MSI/dMMR,gastrointestinal cancers,immune checkpoint inhibitors

Data availability:

Keywords: resistance, MSI/dMMR, gastrointestinal cancers, immune checkpoint inhibitors

The Optimal Therapy after Progression on Immune Checkpoint Inhibitors in MSI Metastatic Gastrointestinal Cancer Patients: A Multicenter Retrospective Cohort Study.

Read this article at

Abstract

Related collections

HLA-G and immune tolerance in pregnancy

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 307

Cited by 3